Skip to main content
Top

The Cardioprotective Effects of Adiponectin in Diabetes

Published in:

Abstract

Purpose of Review

Adiponectin, a hormone secreted by adipocytes, plays a crucial role in maintaining metabolic balance and supporting cardiovascular health. Although it is known for its protective effects, such as improving insulin sensitivity, reducing inflammation, and maintaining endothelial function, there are paradoxical associations between high adiponectin levels and increased cardiovascular mortality—referred to as the “adiponectin paradox”—which complicates its clinical interpretation. This review explores the cardioprotective effects of adiponectin in both type 1 and type 2 diabetes, focusing on its potential to regulate glucose metabolism and prevent cardiovascular complications.

Recent Findings

By reviewing key studies, the article evaluates adiponectin’s diverse roles and compares its effects on cardiovascular outcomes across diabetes subtypes, especially in diabetic cardiomyopathy, with an emphasis on congestive heart failure.

Summary

The findings underscore the importance of further research into therapeutic strategies aimed at modulating adiponectin levels, particularly for individuals with diabetes and congestive heart failure. Understanding the dual nature of adiponectin’s effects is critical for developing target interventions to improve cardiovascular outcomes in diabetic populations.
Title
The Cardioprotective Effects of Adiponectin in Diabetes
Authors
Tara Kazemi
Yuanjie Mao
Tina Zhang
Publication date
13-10-2025
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 1/2025
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-025-01610-5
This content is only visible if you are logged in and have the appropriate permissions.

Raising the standard: ensuring patient safety through minimum requirements for CGM performance

Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.

Supported by:
  • Abbott Diabetes Care
Prof. Chantal Mathieu
Developed by: Springer Health+
Watch now
Video

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits
Fat cells 3D render/© Spectral-Design / Stock.adobe.com, Woman monitoring glucose level with sensor and an app on her phone while training at swimming pool/© (M) Goffkein, stock.adobe.com (symbolic image with model), Person walking/© _KUBE_ / Stock.adobe.com